TrivarX Raises $3.5m to Advance Stabl-Im Brain Tumour Imaging Platform Toward Clinical Trials

An update from TrivarX Limited ( (AU:TRI) ) is now available.

TrivarX Limited has secured $3.5 million from the second tranche of a strategic placement, bolstering its balance sheet and giving it greater financial flexibility to advance its Stabl-Im imaging platform for brain tumour detection. The funds will support manufacturing scale-up, quality-control validation of stable isotope compounds, and regulatory pre-submission activities in the US and EU as the company moves Stabl-Im toward the clinic. Stabl-Im uses stable isotope labelling and standard MRI to safely and non-invasively visualise replicating tumour cells in the brain, potentially offering a breakthrough alternative to radiation-based or surgical methods. The work will be guided by experienced regulatory and medical consultants alongside Stabl-Im founder Dr Daniel Tillett, with a first-in-human Phase 1 trial planned for 2026 to assess safety, imaging precision and reproducibility in patients with confirmed brain tumours, laying the groundwork for broader multi-site trials and strengthening TrivarX’s position in advanced neuro-oncology diagnostics.

More about TrivarX Limited

TrivarX Limited (ASX: TRI, OTCPINK: MDBIF) is a mental health technology company that develops objective measurement tools to aid in the early detection and screening of mental health conditions. Founded in Australia and operating from Perth and Minneapolis, the company targets global healthcare markets through its listings on the ASX and OTCQB Venture Market.

YTD Price Performance: 6.25%

Average Trading Volume: 3,189,093

Technical Sentiment Signal: Sell

Current Market Cap: A$19.61M

See more insights into TRI stock on TipRanks’ Stock Analysis page.